ARIAD Pharmaceuticals (ARIA) : 5 analysts are covering ARIAD Pharmaceuticals (ARIA) and their average rating on the stock is 2.2, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
ARIAD Pharmaceuticals (ARIA) : Currently there are 5 street experts covering ARIAD Pharmaceuticals (ARIA) stock. The most bullish and bearish price target for the stock is $13 and $9 respectively for the short term. The average price target of all the analysts comes to $10.6. The estimated standard deviation from the target is $1.82.
For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, Barclays maintains its outlook on ARIAD Pharmaceuticals (NASDAQ:ARIA). The current rating of the shares is Underweight, according to the research report released by the firm. The brokerage firm raises the price target from $8 per share to $9 per share. The rating by the firm was issued on July 29, 2016.
ARIAD Pharmaceuticals (NASDAQ:ARIA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.69 and $9.53 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.93. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.93, notching a gain of 2.16% for the day. The total traded volume was 5,678,866 . The stock had closed at $9.72 on the previous day.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).